Latest Graft-versus-host disease Stories
PRINCETON, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the third quarter of 2010. Soligenix's revenues for the third quarter of 2010 were approximately $861,000 as compared to $767,000 for the third quarter of 2009. The increased revenues were primarily a result of increases in National Institutes of Health (NIH) grant revenues as the...
PRINCETON, N.J., Nov. 3, 2010 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that the Company has been awarded a cash grant totaling $244,479 under the U.S. Internal Revenue Service's Qualifying Therapeutic Discovery Project (QTDP) program. The awards are intended for projects designed to treat or prevent diseases by conducting studies for the purpose of securing approval from the U.S. Food and...
PRINCETON, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today reported preliminary results from its Phase 2 "proof-of-concept" exploratory clinical trial of orBec® for the prevention of acute Graft-versus-Host disease (GVHD) in patients undergoing myeloablative conditioning regimens with initiation of dosing prior to hematopoietic cell transplantation (HCT) and continuing through the...
NEW YORK, Oct. 19 /PRNewswire/ -- Americord Registry announced its breakthrough placenta stem cell preservation process, the first of its kind, as a new and significantly more effective alternative to private cord blood stem cell banking. The new process, called Cord Plus, preserves up to ten times more stem cells from the placenta than is found on average in a unit of cord blood, which contains only enough stem cells to treat a patient weighing less than 65 pounds. As a result of this...
Dual-Track Medical Conference To Focus on Cutting-Edge Research and Treatments CLEVELAND, Oct. 14 /PRNewswire-USNewswire/ -- The Case Comprehensive Cancer Center, together with the Meredith A. Cowden Foundation, will bring the first national educational conference on Graft vs. Host Disease (GvHD) to Cleveland on Thursday, Nov. 4, 8 a.m. to 6 p.m., at Corporate College East, 4400 Richmond Road, Warrenville Hts. GvHD is a life-threatening complication experienced by an estimated 60 percent of...
PRINCETON, N.J., Sept. 27 /PRNewswire-FirstCall/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced the results of its recent meeting of shareholders as well as an adjustment to the expected timeline to completion for its confirmatory Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host disease (GI GVHD). All four proposals made to shareholders were approved, namely: The election of new Board...
PRINCETON, N.J., Sept. 13 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, announced today that its President and Chief Executive Officer Christopher J. Schaber, Ph.D. will present a company overview highlighting recent developments at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City. The presentation will take place on Wednesday, September 15, 2010 at 10:00AM EDT in the Spellman Salon...
PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program. The grant will be used to defray a significant portion of the costs associated with...
Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology. Overall, these patients were three and a half times more likely to develop a severe or life-threatening health condition, such as cardiovascular, endocrine, or musculoskeletal problems, as well as new cancers, when...
PRINCETON, N.J., Aug. 13 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the second quarter of 2010. Soligenix's revenues for the second quarter of 2010 were approximately $445,000 as compared to $332,000 for the second quarter of 2009. The increased revenues were primarily a result of increases in National Institutes of Health (NIH) grant revenues as the...
